Replies to post #18858 on Amarin Corp Plc (AMRN)

[Dancing in the dark]

the news of sales force lay off
appears to have caused the return of
the "they gotta partner/sell" speculators.

[TCEGGJD]

IMHO AMRN isn't dropping significantly on this news because it's already armageddon priced. Currently, AMRN's market cap is at $300MM plus. Kindly note GSK bought Reliant (developers of Lovaza) for $1.6 billion. Vascepa is generally regarded as a superior drug to Lovaza which currently earns close to $1 billion per year (in the Marine indication plus off-label). To put a roughly equivalent valuation on AMRN would require the share price to be at $9.27 today (not including potential Anchor indication plus other possible markets). To put it succinctly AMRN is very undervalued barring some unforeseen catastrophe.

[BioChica]

The market cap is way to low at this point. It may stay at this level until the company expands on it's strategy going forward!